ArticleThorax2013
How should I interpret an interferon gamma release assay result for tuberculosis infection?
Article in Thorax, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Performance of QuantiFERON tests for detecting latent tuberculosis infections: A Meta-analysis.Immunologic research · 2025Pooled it
- TB-SERS analyzer: Analysis tool for tuberculosis prediction based on Raman spectroscopy with machine learning and convolutional neural network.PLoS computational biology · 2026Article
- BCG-induced trained immunity on clinical outcomes in moderate to severe COVID-19 patients at a tertiary care center: A comparative study based on interferon-gamma release assays status.Journal of family medicine and primary care · 2026Article
- Series 2: Invisible Threats: A Global Scoping Review of Risk Factors for Tuberculosis Infection.Tropical medicine and infectious disease · 2026Review
- Diagnostic efficacy of the TSPOT assay for tuberculosis infection and drug resistance in mycobacterium tuberculosis in patients with malignant tumors.American journal of cancer research · 2026Article
- Whom tuberculosis tests detect and why it matters: implications for diagnostic algorithms.The Lancet. Microbe · 2025Review
- Commentary on: diagnostic accuracy and predictive value of the QuantiFERON-TB Gold Plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study.The Lancet regional health. Europe · 2025Article
- Enhancing the interferon-γ release assay through omission of nil and mitogen values.Respiratory research · 2023Article
- Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis.Scientific reports · 2023Article
- Surgically induced scleral necrosis associated with concomitant tuberculosis infection: a diagnostic challenge.GMS ophthalmology cases · 2023Article
- Interferon-γ release assay screening in biologics: safe and reliable, but not perfect.ERJ open research · 2022Article
- Article
- Screening for Latent Tuberculosis in Children With Immune-mediated Inflammatory Diseases Treated With Anti-tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests.Archives of rheumatology · 2020Article
- Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.Digestive diseases and sciences · 2019Article
- Progress in interferon-gamma release assay development and applications: an unfolding story of translational research.Annals of translational medicine · 2019Article
- B cells response directed against Cut4 and CFP21 lipolytic enzymes in active and latent tuberculosis infections.PloS one · 2018Article
- ORFeome-based identification of biomarkers for serodiagnosis of Mycobacterium tuberculosis latent infection.BMC infectious diseases · 2017Article
- Diagnosis and Management of Latent Tuberculosis Infection.Cold Spring Harbor perspectives in medicine · 2015Review
- Serial QuantiFERON-TB Gold In-Tube assay and tuberculin skin test to diagnose latent tuberculosis in household Mexican contacts: conversion and reversion rates and associated factors using conventional and borderline zone definitions.Memorias do Instituto Oswaldo Cruz · 2014Article
- Tuberculin skin test and ELISPOT/T. SPOT.TB in children and adolescents with juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundInterferon gamma release assays (IGRAs) are the first new diagnostic tests for latent tuberculosis (TB) infection (LTBI) since the century-old tuberculin skin test (TST). They are cell-mediated immune-based blood tests that have revolutionised LTBI diagnosis and are increasingly recommended by national guidelines.
objectivesWith the rapid expansion of the IGRA evidence-base in recent years, the limitations of IGRA and uncertainties in clinical interpretation of IGRA results have increasingly come into focus. In LTBI diagnosis these include: prognostic power of IGRAs relative to TST for quantifying risk of progression to active disease, false-negative rates in immunocompromised patients, the clinical meaning of IGRA reversion and the significance of the size of IGRA response. Furthermore, the role of IGRAs in the diagnostic work-up of active TB is unclear, and there is little evidence supporting use of the tests in anti-TB treatment monitoring. METHODOLOGICAL APPROACH: On-going large prospective longitudinal clinical endpoint cohort studies of active and latent TB will tackle some of the uncertainties regarding IGRAs. Here we discuss clinical practice and guidance in light of the current uncertainties, based on existing evidence. CONCLUSIONS AND IMPACT: Current and planned clinical research will fill the gaps in the evidence-base, narrowing the areas of uncertainty and informing future policy. Translational research into next-generation IGRAs and new T cell-based diagnostic platforms will likely overcome the limitations of current IGRAs in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.